Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
General use-results survey of Alunbrig Tablets in non-small cell lung cancer
jRCT2031210404Recruiting
- Sponsor
- Takeda
- Start
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of brigatinib in non-small cell lung cancer (NSCLC), sponsored by Takeda. Primary endpoint: Number of participants with adverse events related to interstitial lung disease. Started Nov 2021; status: recruiting.
02
Drugs
brigatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031210404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210404.